SCHEMBL16612477

SCHEMBL16612477

CC1(C)OB(c2cccc(OCCCNC(=O)O)c2)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
RECQL P46063 1/20 0.44
KDM4E B2RXH2 3/20 0.43
MTNR1A P48039 2/20 0.42
MTNR1B P49286 2/20 0.42
HIF1A Q16665 1/20 0.42
NSD2 O96028 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 1/20 0.42
LPL P06858 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16612124 0.96 MTNR1A (0.46) L3MBTL1RECQLKDM4EMTNR1AMTNR1B
SCHEMBL23484589 0.87 MTNR1A (0.59) L3MBTL1MTNR1AMTNR1BALDH1A1
SCHEMBL4124783 0.85 CA12 (0.48)
SCHEMBL1561011 0.85 HIF1A (0.47) L3MBTL1RECQLMTNR1AMTNR1BHIF1A
SCHEMBL27075535 0.83 LIPG (0.43) KDM4EHIF1AALDH1A1SMN1; SMN2LPL
SCHEMBL16014145 0.82 PDK2 (0.49) MTNR1AMTNR1BHIF1A
SCHEMBL2801619 0.82 LPL (0.51) ALDH1A1LPLLIPGMAOB
SCHEMBL18124821 0.82 LIPG (0.50) HIF1ALPLLIPG
SCHEMBL27075532 0.81 LIPG (0.44) L3MBTL1MTNR1AMTNR1BHIF1AALDH1A1
SCHEMBL2150010 0.81 HIF1A (0.47) L3MBTL1RECQLHIF1AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751887-B2 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-09-05 US disclosed
EP-2857404-B1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO CO LTD (JP) 2017-08-23 EP disclosed
US-20160046639-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-18 US disclosed
EP-2857404-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR Daiichi Sankyo Co., Ltd. (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046639-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS ROS1, JAK1, ERBB2 L3MBTL1 3907/4885RECQL 3718/4885KDM4E 2596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.